COMPANY RESEARCHThe website offers commercial MicroED using cryo-TEM for structural analysis of powders, small molecules, polymorphs, and mixtures.
Economic Information Daily relays a company announcement; date is the publication date. Now acquired; Series B should not be used as its current independent stage.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
The MicroED page discloses a Talos F200C platform and commercial workflow and discusses small-molecule powders, mixture components, and polymorphs.
Pharmaron's 2025 announcement confirms its acquisition of Biortus. The acquisition price is not classified as company financing.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| MicroED / 3D ED service capabilities | Determined by the submitted sample and research question · Not applicable; service capability | Services / platform | Not applicable; not a human clinical program |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
This article explores how Microcrystal Electron Diffraction (MicroED) is set to revolutionize drug polymorph research workflows. Drawing upon recent news, official websites, and LinkedIn updates from Crystal Pharmatech and Eldico, it clearly distinguishes between verified facts, industry viewpoints, and information pending verification.
Direct Electron lists a REyes webinar for November 10, 2026, at noon Eastern Time. It will discuss diffraction-guided screening, automated acquisition and structure solution, including integration with SerialEM.
Crystal Pharmatech’s November 4 announcement confirms ED-1 service in Suzhou. Its service page describes integration with solid-form screening for small crystals and pharmaceutical solid forms.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.